Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

C K Wong, C W K Lam, A K L Wu, W K Ip, N L S Lee, I H S Chan, L C W Lit, D S C Hui, M H M Chan, S S C Chung, J J Y Sung, C K Wong, C W K Lam, A K L Wu, W K Ip, N L S Lee, I H S Chan, L C W Lit, D S C Hui, M H M Chan, S S C Chung, J J Y Sung

Abstract

Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel coronavirus, but its immunopathological mechanisms have not yet been fully elucidated. We investigated changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS. Cytokine profile of SARS patients showed marked elevation of Th1 cytokine interferon (IFN)-gamma, inflammatory cytokines interleukin (IL)-1, IL-6 and IL-12 for at least 2 weeks after disease onset, but there was no significant elevation of inflammatory cytokine tumour necrosis factor (TNF)-alpha, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2 and Th2 cytokine IL-4. The chemokine profile demonstrated significant elevation of neutrophil chemokine IL-8, monocyte chemoattractant protein-1 (MCP-1), and Th1 chemokine IFN-gamma-inducible protein-10 (IP-10). Corticosteroid reduced significantly IL-8, MCP-1 and IP-10 concentrations from 5 to 8 days after treatment (all P < 0.001). Together, the elevation of Th1 cytokine IFN-gamma, inflammatory cytokines IL-1, IL-6 and IL-12 and chemokines IL-8, MCP-1 and IP-10 confirmed the activation of Th1 cell-mediated immunity and hyperinnate inflammatory response in SARS through the accumulation of monocytes/macrophages and neutrophils.

Figures

Fig. 1
Fig. 1
Box & whiskers plots of changes in plasma cytokine concentrations following day of disease onset in the 20 SARS patients. Normal ranges: (a) IL-1β P < 0·05).
Fig. 1
Fig. 1
Box & whiskers plots of changes in plasma cytokine concentrations following day of disease onset in the 20 SARS patients. Normal ranges: (a) IL-1β P < 0·05).
Fig. 2
Fig. 2
Box & whiskers plots of changes in plasma chemokine concentrations following day of disease onset in the 20 SARS patients. Normal ranges: (a) IL-8 P < 0·05).
Fig. 2
Fig. 2
Box & whiskers plots of changes in plasma chemokine concentrations following day of disease onset in the 20 SARS patients. Normal ranges: (a) IL-8 P < 0·05).
Fig. 3
Fig. 3
Box & whiskers plots of changes in plasma cytokine and chemokine concentrations following day of disease onset in SARS patients (a) treated (n = 13) and (b) not treated (n = 7) with pulsed methylprednisolone. Although not reaching statistical significance, median concentrations in (a) are higher than corresponding values in (b).

References

    1. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986–94.
    1. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1977–85.
    1. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995–2005.
    1. Wong RSM, Wu AKL, To KF, et al. Haematological changes in patients with severe acute respiratory syndrome. Br Med J. 2003;326:1358–62.
    1. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767–72.
    1. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–25.
    1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–76.
    1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–66.
    1. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–404.
    1. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–9.
    1. Poon LL, Wong OK, Chan KH, et al. Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS) Clin Chem. 2003;49:953–5.
    1. Ng EK, Hui DS, Chan KC, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem. 2003;49:1976–80.
    1. Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet. 2003;361:1701–3.
    1. Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev. 2001;65:131–50.
    1. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet. 2002;360:1831–7.
    1. Van Reeth K, Van Gucht S, Pensaert M. In vivo studies on cytokine involvement during acute viral respiratory disease of swine: troublesome but rewarding. Vet Immunol Immunopathol. 2002;87:161–8.
    1. Meduri GU. Host defense response and outcome in ARDS. Chest. 1997;112:1154–8.
    1. Kunkel SL, Lukacs NW, Strieter RM, Chensue SW. The role of chemokines in the immunopathology of pulmonary disease. Forum (Genova) 1999;9:339–55.
    1. World Health Organization. Severe acute respiratory syndrome (SARS) Wkly Epidemiol Rec. 2003;78:81–3.
    1. Wong CK, Lam CWK. Clinical applications of cytokine assays. Adv Clin Chem. 2003;37:1–46.
    1. Tarnok A, Hambsch J, Chen R, Varro R. Cytometric bead array to measure six cytokines in twenty-five microliters of serum. Clin Chem. 2003;49:1000–2.
    1. Evans SW, Whicher JT. The cytokines: physiological and pathophysiological aspects. Adv Clin Chem. 1993;30:1–88.
    1. Leemans JC, Vervoordeldonk MJ, Florquin S, van Kessel KP, van der Poll T. Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am J Respir Crit Care Med. 2002;165:1445–50.
    1. De Waal Malefyt R, Haanen J, Spits H, Roncarolo MG. Interleukin-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915–24.
    1. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today. 1996;17:214–7.
    1. Kennedy MK, Picha KS, Shanebeck KD, Anderson DM, Grabstein KH. Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol. 1994;24:2271–8.
    1. Manetti R, Gerosa F, Giudizi MG, et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med. 1994;179:1273–83.
    1. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells. 1994;12:154–68.
    1. Hendrzak JA, Brunda MJ. Interleukin-12. Biologic activity, therapeutic utility, and role in disease. Lab Invest. 1995;72:619–37.
    1. Martin TR, Goodman RB. Chemokines in acute lung injury. In: Lenfant C, editor. Chemokines in the lung. New York: Marcel Dekker, Inc.; 2003. pp. 189–220.
    1. Steinberg KP, Milberg JA, Martin TR, Maunder RJ, Cockrill BA, Hudson LD. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med. 1994;150:113–22.
    1. Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM, Gadek JE. Lung neutrophils in the adult respiratory distress syndrome. Clinical and pathophysiologic significance. Am Rev Respir Dis. 1986;133:218–25.
    1. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol. 2002;451:1–10.
    1. Chollet-Martin S, Jourdain B, Gibert C, Elbim C, Chastre J, Gougerot-Pocidalo MA. Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Am J Respir Crit Care Med. 1996;154:594–601.
    1. Villard J, Dayer-Pastore F, Hamacher J, Aubert JD, Schlegel-Haueter S, Nicod LP. GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Am J Respir Crit Care Med. 1995;152:1549–54.
    1. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:602–11.
    1. Rosseau S, Hammerl P, Maus U, et al. Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2000;279:L25–35.
    1. Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773–8.
    1. Neumann B, Emmanuilidis K, Stadler M, Holzmann B. Distinct functions of interferon-gamma for chemokine expression in models of acute lung inflammation. Immunology. 1998;95:512–21.
    1. Mo XY, Sarawar SR, Doherty PC. Induction of cytokines in mice with parainfluenza pneumonia. J Virol. 1995;69:1288–91.
    1. Leon LR. Invited review. Cytokine regulation of fever: studies using gene knockout mice. J Appl Physiol. 2002;92:2648–55.
    1. Standiford TJ, Tsai WC. Chemokines in infectious diseases of the lung. In: Lenfant C, editor. Chemokines in the lung. New York: Marcel Dekker, Inc.; 2003. pp. 145–69.
    1. Kurdowska A, Noble JM, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR. Anti-interleukin 8 autoantibody: interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med. 2001;163:463–8.
    1. Dhainaut JF, Charpentier J, Chiche JD. Transforming growth factor-beta: a mediator of cell regulation in acute respiratory distress syndrome. Crit Care Med. 2003;31:S258–64.
    1. Proudfoot AE, Power CA, Wells TN. The strategy of blocking the chemokine system to combat disease. Immunol Rev. 2000;177:246–56.
    1. Luster AD. Antichemokine immunotherapy for allergic diseases. Curr Opin Allergy Clin Immunol. 2001;1:561–7.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi